Tag Archives: Diabetes

Middle East Meltdown: Diabetes in the Arab Context

Diabetes, it can be said, is one of the unpleasant side-effects of being human. Few other medical conditions are so heavily influenced by lifestyle and patterns of individual behavior, reinforced by a mix of economic, social and cultural factors.  Nowhere do these form a more potent combination than in the Arab countries of the Middle East, […]
Posted in Global, healthcare, Op-Ed | Also tagged , | 1 Comment

180 Diabetes Medicines in Development in the U.S.

America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development, all either in clinical trials or under review by FDA, include 30 for type 1 diabetes, 100 for type 2, and 52 for diabetes-related conditions, according to a new report […]
Posted in R&D | Also tagged , | Leave a comment

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, IP, Legal, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , , , , , , | Leave a comment

Bristol-Myers Squibb Sells Diabetes Business to AstraZeneca

Bristol-Myers Squibb has agreed to sell its global diabetes business that was part of its collaboration with AstraZeneca for $2.7 billion with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025. In addition, AstraZeneca will make payments of up to $225 million […]
Posted in Deals, Guest Blog | Also tagged , , | Leave a comment

Ever Bullish, Al Mann Says Afrezza is Coming in Mid-April

Post Exubera, inhaled insulin has been an uphill struggle with regulators. Alfred Mann and MannKind are nonetheless determined to push Afrezza, an ”ultra” rapid-acting mealtime insulin, over the regulatory peak and into the market. Will they succeed, or is MannKind doomed to play Sisyphus on mount FDA? It would be in large part due to […]
Posted in FDA, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , | 3 Comments
  • Categories

  • Meta